Lumen Bioscience’s LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of its RePreve Clinical Trial evaluating LMN-201 for Clostridioides difficile infection (CDI). LMN-201...